Clinical Trial Update: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating whether revaccination with PPS23 is boosted or not by PCV13 in splenectomised patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Splenectomy-related Susceptibility Infection Risk

Drugs mentioned

• PCV13 (pneumococcal conjugate vaccine 13-valent)
• PPS23 (pneumococcal polysaccharide vaccine (PPSV23))

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Splenectomised Patients | Phase 2 | Status: UNKNOWN